醋酸环丙孕酮与脑膜瘤:法国全国性人群研究
CPA组手术年龄中位数47岁,显著低于非CPA组的61岁;肿瘤好发于中颅底(39%)与前颅底(21.9%);CPA剂量越高,多次手术与多发脑膜瘤风险越高;肿瘤分级未受CPA影响。
要点
- CPA相关脑膜瘤手术年龄明显提前,中位47岁对比61岁
- 好发于前、中颅底,呈显著颅底优势分布
- CPA剂量升高与多次手术及多发部位风险相关
核心结论
- 过去10年相当数量CPA相关脑膜瘤被手术切除,改变了女性脑膜瘤手术年龄的整体分布。
- 此类肿瘤发生年龄明显早于常规人群,且优先位于前颅底和中颅底。
研究设计与样本
- 法国全国性人群为基础队列研究,处理SNDS数据库提取2007至2017年间手术病例。
主要发现
- CPA组手术年龄中位数47岁(IQR 42–54),非CPA组61岁(IQR 51–70),p < 0.001。
- CPA开始至手术的中位时间5.5年(IQR 3.1–7.9),处方时中位年龄42岁(IQR 36.7–48.9)。
- 中颅底为最常见部位(39%),前颅底附着占21.9%,颅底优势高度显著(p < 0.001)。
- CPA中位剂量40 g(IQR 19–72),剂量与使用时长强相关(r = 0.58,95%CI 0.54–0.62,p < 0.001)。
- CPA剂量增加提高多次脑膜瘤手术风险(p < 0.001)及多部位脑膜瘤风险(p < 0.001);肿瘤分级未受CPA影响(p = 0.603)。
关键数值与推荐
- 肿瘤分级构成:良性或I级92%,非典型或II级6.1%,恶性或III级1.9%。
临床怎么用
- 女性脑膜瘤患者术前应询问CPA用药史,尤其前、中颅底及多发肿瘤者。
- 对长期或高剂量CPA暴露者应关注多发脑膜瘤及再次手术风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The study the characteristics of surgical meningiomas in female patients who took CPA and to compare this population to a non-CPA control group. MATERIALS AND METHODS: We processed the French Système National des Données de Santé (SNDS) database to retrieve appropriate cases operated between 2007 and 2017. RESULTS: 1 101 female patients (3.8%) who used to take CPA and underwent a meningioma surgery were extracted from a nationwide population based cohort of 28 924 patients. Median age at CPA prescription was 42 years IQR[36.7-48.9]. The median time between CPA start and surgery was 5.5 years IQR[3.1-7.9]. The median age at surgery was significantly lower in patients who were treated by CPA (47 years, IQR[42-54) compared to the non-CPA population (61 years, IQR[51-70], p < 0.001). Median CPA dose was 40 g, IQR[19-72]. There was a strong correlation between CPA dose and duration (r = 0.58, 95%CI[0.54-0.62], p < 0.001). Middle skull base was the most common (39%) location with a anterior skull base insertion being also far more common compared to the usual population with 21.9% of the tumour. This skull base predominance of CPA-associated meningioma is highly significant (p < 0.001). Increased CPA dose raised the risk of having multiple meningioma surgeries (p < 0.001) and multiple meningioma locations (p < 0.001). Tumour grading was not modified by CPA treatment (p = 0.603). Benign or grade I meningioma accounting for 92%, atypical or grade II for 6.1% and malignant or grade III for 1.9%. CONCLUSION: In the past 10 years, a significant number of CPA-induced meningiomas have been removed, modifying the global pyramid of age at surgery for female patients. These tumours occur well before the usual age and are preferentially located on the anterior and middle skull base.
引用
- Champeaux-Depond C, Weller J, Froelich S, et al. Cyproterone acetate and meningioma: a nationwide-wide population based study. J Neurooncol. 2021. PMID: 33394263. doi:10.1007/s11060-020-03672-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。